



## Meda enters partnership for Elestrin in the US market

Meda has entered into a promotion agreement with Mission Pharmacal, a company active in the women's health area, for Meda's topical estrogen replacement therapy product Elestrin.

Elestrin was acquired in 2012 from Jazz Pharmaceuticals and has showed good growth since then. Following the enhanced focus of Meda's US sales force on the allergy and respiratory area, the promotion agreement is a right step that will secure ongoing resources and continued growth for Elestrin.

*"Through this partnership, we optimize sales efforts for Elestrin and at the same time increase our focus on the respiratory area",* said Dr. Jörg-Thomas Dierks, CEO of Meda AB.

---

### For further inquiries, please contact:

Paula Treutiger, Investor Relations

ph: +46 733-666 599

paula.treutiger@meda.se

---

**MEDA AB (publ)** is a leading international specialty pharma company. Meda's products are sold in more than 120 countries worldwide and the company is represented by its own organizations in over 55 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit [www.meda.se](http://www.meda.se).

### Forward-looking statements

*This press release is not an offer to sell or a solicitation to buy shares in Meda. This press release also contains certain forward-looking statements with respect to certain future events and Meda's potential financial performance. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts, and may sometimes include words such as "may", "will", "seek", "anticipate", "expect", "estimate", "intend", "plan", "forecast", "believe" or other words of similar meaning. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to a number of risks and uncertainties. In the event such risks or uncertainties materialize, Meda's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Meda's ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Meda AB's interim or annual reports, prospectuses or press releases. Listeners and readers are cautioned that no forward-looking statement is a guarantee of future performance and that actual result could differ materially from those contained in the forward-looking statements. Meda does not intend, nor undertakes, to update any such forward looking statements.*